Abstract:To explore novel topoisomerase inhibitors with high activity and druggability, 3-aryl isoquinoline alkaloids based on the corydamine modification and preliminary SARs of isoquinoline alkaloids in our previous works were re-designed. Currently, the design strategy is mainly revolved around the rigidity and flexibility of the molecular side chain and the molecular size. Consequently, not only the activity and druggability of the compound could be further improved, also the mechanism behind could been discovered. In vitro pharmacological studies, the outstanding nature with the excellent activity and the researchable depth of azepane-substituted compound 7 has been found through the vitro cytotoxicity test (IC50 = 1.93 μM in HuH7 cells and 2.10 μM in LM9 cells) and topoisomerase test. It was found that compound 7 had dual inhibitory effects on topoisomerase I and II, and its inhibitory activity on topoisomerase II is stronger than the positive drug etoposide. From the perspective of molecular docking, it had been verified that compound 7 could insert between DNA base pairs, which was consistent with the results of the DNA unwinding experiment. And the comet experiment confirmed 7 caused DNA damage. Meanwhile, compound 7 could inhibit cell proliferation, invasion and migration, and induce apoptosis by inhibiting PI3K/Akt/mTOR signaling pathway. Therefore, this study may lay a foundation for the discovery of 3-arylisoquinoline compounds with anti-liver cancer potential.

Antitumor and Topoisomerase Ⅱα Inhibitory Activities of 3-Aryl-7-hydroxyquinolines

Multi-Targeting Exploration of New 2-Aminothiazolyl Quinolones: Synthesis, Antimicrobial Evaluation, Interaction with Dna, Combination with Topoisomerase Iv and Penetrability into Cells

Antitumor agents, 130, Novel 4 beta-arylamino derivatives of 3',4'-didemethoxy-3',4'-dioxo-4-deoxypodophyllotoxin as potent inhibitors of human DNA topoisomerase II.

Design and Synthesis of 2-Phenylnaphthalenoids As Inhibitors of DNA Topoisomeraseiiα and Antitumor Agents.

Synthesis and biological evaluation of benzo[a]phenazine derivatives as a dual inhibitor of topoisomerase I and II.

Synthesis and Biological Evaluation of Xanthone Derivatives As Anti-Cancer Agents Targeting Topoisomerase II and DNA

Synthesis, Cytotoxicity and Structure-Activity Relationship of Indolizinoquinolinedione Derivatives As DNA Topoisomerase IB Catalytic Inhibitors

Synthesis and Biological Evaluation of 6-Fluoro-3-phenyl-7-piperazinyl Quinolone Derivatives As Potential Topoisomerase I Inhibitors.

Design, Synthesis and Antitumor Activity of 3-Substituted Quinolone Derivatives (I)

Design, Synthesis, and Cytotoxicity of Indolizinoquinoxaline-5,12-Dione Derivatives, Novel Dna Topoisomerase Ib Inhibitors

Discovery of a Novel Series of Quinolone and Naphthyridine Derivatives As Potential Topoisomerase I Inhibitors by Scaffold Modification.

Design, Synthesis and Biological Evaluation of 3-Arylisoquinoline Derivatives As Topoisomerase I and II Dual Inhibitors for the Therapy of Liver Cancer.

Synthesis and Biological Evaluation of 6-Substituted Indolizinoquinolinediones As Catalytic DNA Topoisomerase I Inhibitors.

Design and Synthesis of 2-Phenylnaphthalenoids and 2-Phenylbenzofuranoids As DNA Topoisomerase Inhibitors and Antitumor Agents

Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors.

Synthesis and Mechanism Studies of 1,3-Benzoazolyl Substituted Pyrrolo[2,3-b]pyrazine Derivatives As Nonintercalative Topoisomerase II Catalytic Inhibitors.

Synthesis and biological evaluation of 5-aminoethyl benzophenanthridone derivatives as DNA topoisomerase IB inhibitors.

Synthesis and biological evaluations of novel indenoisoquinolines as topoisomerase I inhibitors.

Design, Synthesis and Biological Evaluation of 1,4-Dihydroxyanthraquinone Derivatives As Anticancer Agents

Design and synthesis of Aza-boeravinone derivatives as potential novel topoisomerase I inhibitors

Design, synthesis and biological evaluation of 3-substituted indenoisoquinoline derivatives as topoisomerase I inhibitors